[go: up one dir, main page]

AUPS317102A0 - Transdermal aerosol compositions - Google Patents

Transdermal aerosol compositions

Info

Publication number
AUPS317102A0
AUPS317102A0 AUPS3171A AUPS317102A AUPS317102A0 AU PS317102 A0 AUPS317102 A0 AU PS317102A0 AU PS3171 A AUPS3171 A AU PS3171A AU PS317102 A AUPS317102 A AU PS317102A AU PS317102 A0 AUPS317102 A0 AU PS317102A0
Authority
AU
Australia
Prior art keywords
aerosol compositions
transdermal aerosol
transdermal
compositions
aerosol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPS3171A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drug Delivery Solutions Pty Ltd
Original Assignee
Drug Delivery Solutions Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drug Delivery Solutions Pty Ltd filed Critical Drug Delivery Solutions Pty Ltd
Priority to AUPS3171A priority Critical patent/AUPS317102A0/en
Publication of AUPS317102A0 publication Critical patent/AUPS317102A0/en
Priority to BR0312004-0A priority patent/BR0312004A/en
Priority to JP2004514437A priority patent/JP2005533795A/en
Priority to EP03732114A priority patent/EP1534241A1/en
Priority to EA200500082A priority patent/EA007351B1/en
Priority to PCT/AU2003/000784 priority patent/WO2004000275A1/en
Priority to AU2003238543A priority patent/AU2003238543B2/en
Priority to NZ537435A priority patent/NZ537435A/en
Priority to CA002490325A priority patent/CA2490325A1/en
Priority to KR1020047020967A priority patent/KR20050071373A/en
Priority to US11/019,121 priority patent/US20050186141A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AUPS3171A 2002-06-25 2002-06-25 Transdermal aerosol compositions Abandoned AUPS317102A0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AUPS3171A AUPS317102A0 (en) 2002-06-25 2002-06-25 Transdermal aerosol compositions
KR1020047020967A KR20050071373A (en) 2002-06-25 2003-06-24 Transdermal aerosol compositions
EA200500082A EA007351B1 (en) 2002-06-25 2003-06-24 Pharmaceutical composition for transdermal delivery of physiologically active agents
JP2004514437A JP2005533795A (en) 2002-06-25 2003-06-24 Transdermal aerosol composition
EP03732114A EP1534241A1 (en) 2002-06-25 2003-06-24 Transdermal aerosol compositions
BR0312004-0A BR0312004A (en) 2002-06-25 2003-06-24 Transdermal Aerosol Compositions
PCT/AU2003/000784 WO2004000275A1 (en) 2002-06-25 2003-06-24 Transdermal aerosol compositions
AU2003238543A AU2003238543B2 (en) 2002-06-25 2003-06-24 Transdermal aerosol compositions
NZ537435A NZ537435A (en) 2002-06-25 2003-06-24 Transdermal aerosol compositions
CA002490325A CA2490325A1 (en) 2002-06-25 2003-06-24 Transdermal aerosol compositions
US11/019,121 US20050186141A1 (en) 2002-06-25 2004-12-22 Transdermal aerosol compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPS3171A AUPS317102A0 (en) 2002-06-25 2002-06-25 Transdermal aerosol compositions

Publications (1)

Publication Number Publication Date
AUPS317102A0 true AUPS317102A0 (en) 2002-07-18

Family

ID=3836730

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPS3171A Abandoned AUPS317102A0 (en) 2002-06-25 2002-06-25 Transdermal aerosol compositions

Country Status (9)

Country Link
EP (1) EP1534241A1 (en)
JP (1) JP2005533795A (en)
KR (1) KR20050071373A (en)
AU (1) AUPS317102A0 (en)
BR (1) BR0312004A (en)
CA (1) CA2490325A1 (en)
EA (1) EA007351B1 (en)
NZ (1) NZ537435A (en)
WO (1) WO2004000275A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0312007B1 (en) * 2002-06-25 2015-04-14 Acrux Dds Pty Ltd Pharmaceutical composition for transcutaneous administration of testosterone or fentanyl and use of said composition
CA2546404A1 (en) * 2003-11-19 2005-06-02 Acrux Dds Pty Ltd. Method and composition for treatment or prophylaxis of amyloidosis disorders
US20060263421A1 (en) 2005-05-18 2006-11-23 Abeille Pharmaceuticals Inc Transdermal Method and Patch for Nausea
BRPI0819235A2 (en) * 2007-11-02 2017-08-22 Acrux Dds Pty Ltd TRANSDERMAL DELIVERY SYSTEM FOR HORMONES AND STEROIDS
WO2012112348A1 (en) * 2011-02-15 2012-08-23 Eli Lilly And Company Methods for controlling pain in canines using a transdermal solution of fentanyl
WO2012112355A1 (en) * 2011-02-15 2012-08-23 Eli Lilly And Company Methods for controlling pain in equines using a transdermal solution of fentanyl
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212951A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082866A (en) * 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6004969A (en) * 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
JP2002536319A (en) * 1999-02-05 2002-10-29 シプラ・リミテッド Topical spray
IN191090B (en) * 2000-08-29 2003-09-20 Ranbanx Lab Ltd

Also Published As

Publication number Publication date
CA2490325A1 (en) 2003-12-31
EP1534241A1 (en) 2005-06-01
EA200500082A1 (en) 2005-06-30
KR20050071373A (en) 2005-07-07
BR0312004A (en) 2005-03-29
JP2005533795A (en) 2005-11-10
WO2004000275A1 (en) 2003-12-31
EA007351B1 (en) 2006-10-27
NZ537435A (en) 2006-02-24

Similar Documents

Publication Publication Date Title
AU2003299034A1 (en) Transdermal compositions
AU2003275719A1 (en) Deodorant composition
AU2003285288A1 (en) Composition
AU2003254863A1 (en) Herbicide compositions
AU2003262747A1 (en) Compounds, compositions, and methods
AU2003236527A1 (en) Compounds, compositions, and methods
AU2003265242A1 (en) Compounds, compositions, and methods
AU2003291103A1 (en) Pharmaceutical composition
AU2003288133A1 (en) Herbidical composition
AU2003270015A1 (en) Compounds, compositions, and methods
EP1400571A3 (en) Aerosol composition
AU2003256805A1 (en) Compounds compositions and methods
AU2002950744A0 (en) Composition
AU2003250372A1 (en) Pharmaceutical composition
AU2003218121A1 (en) Lotion compositions
AU2002362187A1 (en) Spraying composition
AU2003277079A1 (en) Compounds, compositions, and methods
AU2003276710A1 (en) Deodorant composition
AU2003235708A1 (en) Polytartrate composition
AU2003236353A1 (en) Photopolymerizable composition
AU2003226487A1 (en) Formulation
AU2003208411A1 (en) Anti-glycolytic composition
AU2003269904A1 (en) Antigen-polymer compositions
AU2003217110A1 (en) Novel formulation
AUPS317102A0 (en) Transdermal aerosol compositions